9th Circ. Tosses Amgen Off-Label Marketing MDL
The U.S. Court of Appeals for the Ninth Circuit on Thursday affirmed a 2009 decision by the U.S. District Court for the Central District of California, agreeing with the lower court's finding that Amgen had not committed fraud simply by marketing the drugs for off-label uses.
“The complaint did not...
To view the full article, register now.